|
|
|
| Metoprolol Combined with Eplidone in the Treatment of 52 Cases of Hypertension with Heart Failure |
| ZHOU Lin |
| the Fourth People's Hospital of Zigong City, Sichuan Province, 643000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy and safety of metoprolol combined with eplidone in the treatment of hypertensive heart failure. 【Methods】 A total of 104 patients with hypertensive heart failure who were treated in our hospital were enrolled in the study. The patients were divided into two groups,control group (n=52) and observation group (n=52). View Blood pressure, amino terminal brain natriuretic peptide precursor (NT-proBNP), 6min walking test distance (6MWT), cardiac function index, clinical efficacy and adverse reaction rate were observed before and after treatment in two groups. 【Results】 The total effective rate of the observation group was 92.31% (48/52), significantly higher than that of the control group 67.31% (35/52), the difference was statistically significant (P<0.05). After treatment, SBP, DBP and NT-proBNP in plasma of the two groups were lower than before treatment, and 6MWT was higher than before treatment. SBP, DBP and NT-proBNP, 6MWT in plasma of the observation group were significantly improved compared with the control group (P<0.05). After treatment, LVEDd and LVESD of the two groups were lower than before treatment, LVEF was higher than before treatment, NYHA classification was better than before treatment, and the heart function index and NYHA classification of the observation group were better than that of the control group, the difference was statistically significant (P>0.05). During the treatment of the two groups, the incidence of adverse reactions such as nausea and vomiting, slow heart rate, dizziness, rash, hyperkalemia, joint pain were compared, and the difference was not statistically significant (11.54% vs 9.62%,P>0.05).【Conclusion】 Metoprolol combined with eplidone has a good clinical effect in the treatment of hypertension combined with heart failure. It can significantly reduce the blood pressure of patients, improve the heart function of patients, and has a high safety. It is worth clinical application.
|
|
Received: 06 May 2019
|
|
|
|
|
|
[1] 杨晶敏.螺内酯、特拉唑嗪、比索洛尔对难治性高血压患者的治疗效果及安全性研究[J].中国全科医学,2018,21(31):3845-3849.
[2] 徐小明,高翔,刘鹏,等.美托洛尔联合贝那普利治疗老年原发性高血压合并心力衰竭的临床疗效及安全性分析[J].心脑血管病防治,2015,15(6):471-472.
[3] 王敏.依普利酮片治疗轻中度原发性高血压的有效性和安全性的初步研究[J].中国循环杂志,2013,28(8):590-594.
[4] 魏英贤.贝那普利联合美托洛尔治疗老年原发性高血压合并心力衰竭疗效观察[J].中华实用诊断与治疗杂志,2016,30(10):1036-1038.
[5] 林毅. 厄贝沙坦治疗高血压伴心力衰竭的疗效及其对血清hsCR、BNP水平的影响[J].中国老年学杂志,2013,33(9):2184-2185.
[6] 邓芸,陈宝峰,肖雨雄,等.美托洛尔对慢性心力衰竭患者左室扭转异常的改善作用[J].广东医学,2013,34(17):2706-2708.
[7] 杨尹鉴,樊朝美. 新型醛固酮受体阻滞剂——依普利酮研究进展[J]. 中国临床药理学杂志, 2014,29(5):389-400.
[8] 林青,刘宝宏,李治民,等.洛汀新联合螺内酯对原发性高血压合并心力衰竭患者心功能及BNP、CRP的影响[J].中国循证心血管医学杂志,2014,9(4):436-442.
[9] 刘静娣.贝那普利联合吲达帕胺治疗高血压合并心力衰竭的疗效观察[J].现代中西医结合杂志,2014,23(8):874-875. |
|
|
|
2020, Vol. 37 
